P02-027 - Quality of life in CAPS treated by Canakinumab


Methods Patients were those first included in the pivotal (D2304) and in the extension (D2306) Canakinumab/CAPS study [1] and followed in the reference center for autoinflammatory diseases at Bicêtre Hospital (Paris). All carried a heterozygous mutation in the NLPR3 gene and had received Canakinumab (dose of 150 mg every 8 weeks or 2mg/kg for patient weight… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics